Abstract
The NF-κB transcription factor is a central mediator of immune response and inflammation. Several lines of evidence also support a role for NF-κB in oncogenesis and cancer progression. However, with the exception of the oncoprotein v-Rel, a direct oncogenicity by Rel/NF-κB proteins has not yet been demonstrated. It is conceivable that, according to the cellular context and the stage of cancer, an activation or an inhibition of cellular NF-κB activity might participate in tumor progression. On another hand, NF-κB is clearly involved in the control of apoptosis and cellular response to DNA damage following treatment with cytotoxic anticancer treatments. NF-κB inhibits apoptosis after cellular treatment with TNF-α or DNA-damaging agents. Therefore, the development of drugs that inhibit NF-κB should allow a significant increase of cytotoxicity induced by anticancer chemotherapy.
Translated title of the contribution | The NF-κB transcription factor: Role in oncogenesis and in response to anticancer therapeutics |
---|---|
Original language | French |
Pages (from-to) | 566-571 |
Number of pages | 6 |
Journal | Medecine/Sciences |
Volume | 14 |
Issue number | 5 |
Publication status | Published - May 1998 |
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)